8-K Announcements
6Material company update
May 22, 2026·SEC
Material company update
May 12, 2026·SEC
Material company update
Apr 22, 2026·SEC
Maze Therapeutics, Inc.(MAZE)Earnings, Financials & Key Ratios
MAZE•NASDAQ
Price updated Jun 11, 2026
AboutMaze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs includes MZE829, an oral small molecule inhibitor of apolipoprotein L1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.Show more
- Revenue$0-100.0%
- EBITDA-$140M-330.8%
- Net Income-$131M-351.0%
- EPS (Diluted)-3.05-4020.3%
- ROE-47.52%-194.1%
- ROIC-99.35%-165.8%
- Debt/Equity0.07-51.4%
MAZE Key Insights
Maze Therapeutics, Inc. (MAZE) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Healthy 5Y average net margin of 31.2%
✗Weaknesses
- ✗Weak momentum: RS Rating 17 (bottom 17%)
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when MAZE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MAZE Price & Volume
Maze Therapeutics, Inc. (MAZE) stock price & volume — 10-year historical chart
Loading chart...
MAZE Growth Metrics
Maze Therapeutics, Inc. (MAZE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-88.06%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-335.93%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-4396.88%
Return on Capital
10 Years-49.77%
5 Years-49.77%
3 Years-37.71%
Last Year-48.08%
MAZE Recent Earnings
Maze Therapeutics, Inc. (MAZE) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/11 qtrs (50%)●Beat Revenue 1/11 qtrs (100%)
Q2 2026Latest
May 12, 2026EPS
$0.45
Est $0.43
-4.7%
Revenue
$20M
Est $11M
+88.2%
Q2 2026
Mar 25, 2026EPS
$0.65
Est $0.73
+11.0%
Revenue
—
Est $375,000
Q4 2025
Nov 6, 2025EPS
$0.66
Est $0.74
+10.8%
Revenue
—
Q3 2025
Aug 12, 2025EPS
$0.77
Est $0.79
+2.5%
Revenue
—
Est $3M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.45vs $0.43-4.7% | $20Mvs $11M+88.2% |
| Q2 2026 | Mar 25, 2026 | $0.65vs $0.73+11.0% | —vs $375,000 |
| Q4 2025 | Nov 6, 2025 | $0.66vs $0.74+10.8% | — |
| Q3 2025 | Aug 12, 2025 | $0.77vs $0.79+2.5% | —vs $3M |
Based on last 11 quarters of dataView full earnings history →
MAZE Peer Comparison
Maze Therapeutics, Inc. (MAZE) competitors in Metabolic and Obesity Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RARE | 2.36B | 23.98 | -4.11 | 20.13% | -91.03% | -6.08% | ||
 FOLD | 4.55B | 14.49 | -164.85 | 20.05% | -4.27% | -12.02% | 1.76 | |
 ACMR | 6.07B | 91.70 | 66.93 | 15.24% | 9.48% | 5.13% | 0.16 | |
 BEAM | 3.02B | 29.41 | -36.31 | 120.01% | -49.17% | -5.89% | 0.24 | |
 NTLA | 1.39B | 12.35 | -3.24 | 16.92% | -5.97% | -57.27% | 0.14 | |
 ARWR | 10.48B | 74.41 | -6099.18 | 232.58% | -48.38% | -55.09% | 0.73 | |
 ALNY | 38.61B | 289.39 | 124.20 | 65.19% | 13.46% | 98.29% | 1.62 | |
 IONS | 12.2B | 73.82 | -31.02 | 33.87% | -30.87% | -58.57% | 5.35 |
Compare MAZE vs Peers
Maze Therapeutics, Inc. (MAZE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MAZE Income Statement
Maze Therapeutics, Inc. (MAZE) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 167.5M | 0 | 20M |
Revenue Growth % | - | - | - | -100% | -88.06% |
Cost of Goods Sold | 0 | 0 | 0 | 2.4M | 1.59M |
COGS % of Revenue | - | - | - | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | 167.5M▲ 0% | -2.4M▼ 101.4% | 18.41M▲ 0% |
Gross Margin % | - | - | 100% | - | 92.04% |
Gross Profit Growth % | - | - | - | -101.43% | - |
Operating Expenses | 111.03M | 98.55M | 109.91M | 140.5M | 152.46M |
OpEx % of Revenue | - | - | 65.62% | - | - |
Selling, General & Admin | 22.83M | 24.61M | 26.42M | 34.45M | 39.03M |
SG&A % of Revenue | - | - | 15.77% | - | - |
Research & Development | 88.19M | 73.94M | 83.5M | 108.45M | 114.57M |
R&D % of Revenue | - | - | 49.85% | - | - |
Other Operating Expenses | 0 | 0 | 0 | -2.4M | -1.15M |
Operating Income | -111.03M▲ 0% | -98.55M▲ 11.2% | 57.59M▲ 158.4% | -142.9M▼ 348.1% | -134.05M▲ 0% |
Operating Margin % | - | - | 34.38% | - | -670.25% |
Operating Income Growth % | - | 11.24% | 158.43% | -348.15% | - |
EBITDA | -107.21M | -94.46M | 60.88M | -140.5M | -131.89M |
EBITDA Margin % | - | - | 36.35% | - | -659.44% |
EBITDA Growth % | - | 11.89% | 164.45% | -330.76% | -347.77% |
D&A (Non-Cash Add-back) | 3.82M | 4.09M | 3.3M | 2.4M | 2.16M |
EBIT | -111.03M | -98.55M | 57.59M | -142.9M | -128.38M |
Net Interest Income | 2.03M | 1.97M | 4.65M | 0 | 8.3M |
Interest Income | 2.03M | 1.97M | 4.65M | 0 | 9.16M |
Interest Expense | 0 | 0 | 0 | 0 | 866K |
Other Income/Expense | -3.91M | -1.86M | -4.18M | 11.78M | 11.51M |
Pretax Income | -114.94M▲ 0% | -100.42M▲ 12.6% | 53.4M▲ 153.2% | -131.12M▼ 345.5% | -122.54M▲ 0% |
Pretax Margin % | - | - | 31.88% | - | -612.71% |
Income Tax | 0 | 0 | 1.17M | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 2.19% | 0% | 0% |
Net Income | -114.94M▲ 0% | -100.42M▲ 12.6% | 52.23M▲ 152.0% | -131.12M▼ 351.0% | -122.54M▲ 0% |
Net Margin % | - | - | 31.18% | - | -612.71% |
Net Income Growth % | - | 12.64% | 152.02% | -351.04% | -335.93% |
Net Income (Continuing) | -114.94M | -100.42M | 52.23M | -131.12M | -122.54M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -2.63▲ 0% | -2.29▲ 12.6% | 0.08▲ 103.4% | -3.05▼ 4020.3% | -2.27▲ 0% |
EPS Growth % | - | 12.64% | 103.39% | -4020.31% | -4396.88% |
EPS (Basic) | -2.63 | -2.29 | 0.08 | -3.05 | - |
Diluted Shares Outstanding | 43.78M | 43.78M | 43.8M | 42.98M | 53.9M |
Basic Shares Outstanding | 43.78M | 43.78M | 43.8M | 42.98M | 53.9M |
Dividend Payout Ratio | - | - | - | - | - |
MAZE Balance Sheet
Maze Therapeutics, Inc. (MAZE) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|
Total Current Assets | 106.15M | 34.11M | 201.67M | 349.72M | 379.78M |
Cash & Short-Term Investments | 99.92M | 29.16M | 196.81M | 341.92M | 352.38M |
Cash Only | 99.92M | 29.16M | 196.81M | 189.25M | 198.77M |
Short-Term Investments | 0 | 0 | 0 | 152.67M | 153.62M |
Accounts Receivable | 0 | 0 | 0 | 0 | 20M |
Days Sales Outstanding | - | - | - | - | 94.44 |
Inventory | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - |
Other Current Assets | 6.23M | 4.95M | 4.86M | 7.8M | 7.4M |
Total Non-Current Assets | 43.81M | 37.39M | 38.87M | 47.41M | 39.93M |
Property, Plant & Equipment | 41.23M | 34.98M | 29.92M | 25.16M | 23.97M |
Fixed Asset Turnover | - | - | 5.60x | - | 0.77x |
Goodwill | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 1.21M | 1.09M | 1.09M | 18.11M | 20.29M |
Other Non-Current Assets | 1.37M | 1.32M | 7.87M | 4.14M | 15.96M |
Total Assets | 149.96M▲ 0% | 71.5M▼ 52.3% | 240.54M▲ 236.4% | 397.13M▲ 65.1% | 419.71M▲ 0% |
Asset Turnover | - | - | 0.70x | - | 0.05x |
Asset Growth % | - | -52.32% | 236.4% | 65.1% | 251.12% |
Total Current Liabilities | 20.78M | 16.32M | 20.67M | 22.56M | 21.24M |
Accounts Payable | 1.58M | 2.02M | 1.94M | 1.79M | 4.01M |
Days Payables Outstanding | - | - | - | 272.5 | 710.23 |
Short-Term Debt | 0 | 0 | 0 | 0 | 4.84M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 7.49M | 2.93M | 6.02M | 10.85M | 12.38M |
Current Ratio | 5.11x | 2.09x | 9.76x | 15.50x | 17.88x |
Quick Ratio | 5.11x | 2.09x | 9.76x | 15.50x | 17.88x |
Cash Conversion Cycle | - | - | - | - | -615.78 |
Total Non-Current Liabilities | 27.73M | 45.13M | 22.96M | 19.61M | 56.77M |
Long-Term Debt | 0 | 20.08M | 0 | 0 | 38.83M |
Capital Lease Obligations | 27.73M | 25.05M | 22M | 18.51M | 75.77M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 969K | 1.09M | 388K |
Total Liabilities | 48.51M | 61.45M | 43.64M | 42.16M | 78.01M |
Total Debt | 32.05M | 49.62M | 26.63M | 23.31M | 61.22M |
Net Debt | -67.86M | 20.46M | -170.18M | -165.94M | -137.54M |
Debt / Equity | 0.32x | 4.94x | 0.14x | 0.07x | 0.18x |
Debt / EBITDA | - | - | 0.44x | - | -0.46x |
Net Debt / EBITDA | - | - | -2.80x | - | 1.04x |
Interest Coverage | - | - | - | - | -148.24x |
Total Equity | 101.44M▲ 0% | 10.05M▼ 90.1% | 196.9M▲ 1858.5% | 354.97M▲ 80.3% | 341.7M▲ 0% |
Equity Growth % | - | -90.09% | 1858.46% | 80.27% | 579.06% |
Book Value per Share | 2.32 | 0.23 | 4.50 | 8.26 | 6.34 |
Total Shareholders' Equity | 101.44M | 10.05M | 196.9M | 354.97M | 341.7M |
Common Stock | 21K | 22K | 2K | 49K | 50K |
Retained Earnings | -295.27M | -395.69M | -358.43M | -489.55M | -513.75M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 110K | -135K |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
MAZE Cash Flow Statement
Maze Therapeutics, Inc. (MAZE) cash flow — operating, investing & free cash flow history
| Metric | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|
Cash from Operations | -99.2M | -86.83M | 75.95M | -111.94M | -121.54M |
Operating CF Margin % | - | - | 45.35% | - | - |
Operating CF Growth % | - | 12.48% | 187.48% | -247.38% | -182.93% |
Net Income | -114.94M | -100.42M | 52.23M | -131.12M | -122.54M |
Depreciation & Amortization | 3.82M | 4.09M | 3.3M | 2.4M | 2.16M |
Stock-Based Compensation | 6.74M | 8.75M | 9.65M | 16.4M | 13.17M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 8.42M | 7.07M | 12.3M | 2.65M | 8.23M |
Working Capital Changes | -3.24M | -6.32M | -1.52M | -2.27M | -22.56M |
Change in Receivables | 0 | 0 | 0 | 0 | -20M |
Change in Inventory | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -3.78M | 399K | -204K | -27K | 1.61M |
Cash from Investing | -3.17M | -441K | -1.15M | -170.96M | -164.39M |
Capital Expenditures | -1.97M | -441K | -1.15M | -794K | -588K |
CapEx % of Revenue | - | - | 0.68% | - | 2.94% |
Acquisitions | -1.2M | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 1.73M | 16.39M | 92.85M | 275.34M | 190.32M |
Debt Issued (Net) | 0 | 16.18M | 24.48M | 0 | 38.52M |
Equity Issued (Net) | 1.73M | 209K | 68.37M | 275.84M | -120.32M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | 0 | -500K | 272.12M |
Net Change in Cash | -100.64M▲ 0% | -70.88M▲ 29.6% | 167.65M▲ 336.5% | -7.57M▼ 104.5% | -95.61M▲ 0% |
Free Cash Flow | -101.17M▲ 0% | -87.27M▲ 13.7% | 74.81M▲ 185.7% | -112.73M▼ 250.7% | -122.13M▲ 0% |
FCF Margin % | - | - | 44.66% | - | -610.63% |
FCF Growth % | - | 13.74% | 185.72% | -250.7% | -277.74% |
FCF per Share | -2.31 | -1.99 | 1.71 | -2.62 | -2.27 |
FCF Conversion (FCF/Net Income) | 0.86x | 0.86x | 1.45x | 0.85x | 1.00x |
Interest Paid | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 1.23M | 0 | 0 |
MAZE Key Ratios
Maze Therapeutics, Inc. (MAZE) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|
| Return on Equity (ROE) | -180.12% | 50.48% | -47.52% | -36.63% |
| Return on Invested Capital (ROIC) | -230.63% | 150.91% | -99.35% | -79.99% |
| Gross Margin | - | 100% | - | 92.04% |
| Net Margin | - | 31.18% | - | -612.71% |
| Debt / Equity | 4.94x | 0.14x | 0.07x | 0.18x |
| Interest Coverage | - | - | - | -148.24x |
| FCF Conversion | 0.86x | 1.45x | 0.85x | 1.00x |
| Revenue Growth | - | - | -100% | -88.06% |
Related:MAZE Dividend History·MAZE Revenue History·MAZE Price History·MAZE P/E History·MAZE Financial Ratios·MAZE Institutional Holders
MAZE SEC Filings & Documents
Maze Therapeutics, Inc. (MAZE) SEC filings — annual & quarterly reports (10-K, 10-Q)
MAZE Frequently Asked Questions
Maze Therapeutics, Inc. (MAZE) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Maze Therapeutics, Inc. (MAZE) reported $20.0M in revenue for fiscal year 2025.
Maze Therapeutics, Inc. (MAZE) saw revenue decline by 100.0% over the past year.
Maze Therapeutics, Inc. (MAZE) reported a net loss of $122.5M for fiscal year 2025.
Dividend & Returns
Maze Therapeutics, Inc. (MAZE) has a return on equity (ROE) of -47.5%. Negative ROE indicates the company is unprofitable.
Maze Therapeutics, Inc. (MAZE) had negative free cash flow of $122.1M in fiscal year 2025, likely due to heavy capital investments.